VIVOS INC

vivos-inc-logo

Vivos Inc develops manufacturing equipments for the production of medical isotopes used in diagnosis and treatment of diseases.

#SimilarOrganizations #People #Website #More

VIVOS INC

Social Links:

Industry:
Biotechnology Health Care Manufacturing Medical Device

Founded:
2006-01-01

Address:
Kennewick, Washington, United States

Country:
United States

Website Url:
http://www.radiogel.com

Total Employee:
1+

Status:
Active

Contact:
509.736.4000

Email Addresses:
[email protected]

Total Funding:
875 K USD

Technology used in webpage:
Domain Not Resolving Euro Google Tag Manager Google Analytics Content Delivery Network LetsEncrypt HSTS Nginx Facebook Pixel Facebook Custom Audiences


Similar Organizations

advanced-ultra-violet-systems-logo

Advanced Ultra-Violet Systems

Advanced Ultra-Violet Systems develops UV-C disinfection products for healthcare, education, hospitality, and business environments.

advantigen-biosciences-logo

AdvantiGen Biosciences

AdvantiGen Biosciences develops protein-based tools for research and pharmaceutical industries, focusing on improving human health.

sesen-bio-inc-logo

Sesen Bio, Inc.

Sesen Bio, Inc. is focused on developing innovative protein-based therapeutics to improve human health and treat diseases.

somalogic-logo

SomaLogic

SomaLogic is a protein biomarker discovery and clinical diagnostics company, offers SOMAmer technology to improve diagnostic products.

Current Employees Featured

james-c-katzaroff_image

James C. Katzaroff
James C. Katzaroff CEO, Chairman and Founder @ Vivos Inc
CEO, Chairman and Founder
2008-06-01

leonard-bruce-jolliff_image

Leonard Bruce Jolliff
Leonard Bruce Jolliff Chief Financial Officer @ Vivos Inc
Chief Financial Officer
2006-01-01

donald-a-ludwig_image

Donald A. Ludwig
Donald A. Ludwig Director of Special Projects @ Vivos Inc
Director of Special Projects

nigel-r-stevenson_image

Nigel R. Stevenson
Nigel R. Stevenson Chief Science Officer @ Vivos Inc
Chief Science Officer

maren-ohaks-katzaroff_image

Maren Ohaks Katzaroff
Maren Ohaks Katzaroff Director - Strategic Planning @ Vivos Inc
Director - Strategic Planning

Founder


james-c-katzaroff_image

James C. Katzaroff

Stock Details


Company's stock symbol is OTCPINK:RDGL

Official Site Inspections

http://www.radiogel.com Semrush global rank: 8.5 M Semrush visits lastest month: 523

  • Host name: a16e665f42988324c.awsglobalaccelerator.com
  • IP address: 13.248.243.5
  • Location: Seattle United States
  • Latitude: 47.6348
  • Longitude: -122.3451
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98109

Loading ...

More informations about "Vivos Inc"

RadioGelâ„¢

RadioGel® is a division of Vivos Inc. and holds the patent for a next generation cancer treatment - Precision Radionuclide Therapy (PRnT)â„¢ The future of cancer treatment – the insertion of our radionuclide device directly into the tumor …See details»

Meet The Team - RadioGelâ„¢

Carlton M. Cadwell. Dr. Carlton Cadwell leverages over 30 years of experience in the corporate world leading Cadwell Laboratories, a major international provider of neurodiagnostic devices.See details»

Vivos Inc.

RadioGel®, not currently approved for human use, is our division dedicated to treating cancer in humans using our patented Precision Radionuclide Therapyâ„¢ (PRnTâ„¢). RadioGel® is a hydrogel liquid containing tiny yttrium-90 phosphate …See details»

RAdioGel®. - vivosinc.com

Our RadioGel® division assembled a team of talented and dedicated professionals who are passionate about improving cancer treatment through cutting edge technology and an …See details»

Vivos Inc. - RadioGelâ„¢

Currently RadioGel® is not approved for human therapy. Vivos Inc. (OTCQB: RDGL) Our patented Precision Radionuclide Therapyâ„¢ (PRnTâ„¢) is the future of cancer treatment – the …See details»

RadioGelâ„¢ - LinkedIn

RadioGelâ„¢ Biotechnology Research Richland, Washington 101 followers RadioGelâ„¢ is an yttrium-90 (90-Y) based Precision Radionuclide Therapy (PRnT) device to destroy cancer tumors in humans.See details»

Vivos Inc. Submits the Application to the FDA for Authority to …

Jun 28, 2024 RadioGel ® is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor. The hydrogel is a yttrium-90 carrier at room …See details»

Radiogelâ„¢ Precision Radionuclide Therapy ... - Markets Insider

Dec 20, 2023 RadioGel â„¢ is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor. The hydrogel is a yttrium-90 …See details»

Radiogel Precision Radionuclide Therapy Receives FDA ... - Nasdaq

Dec 20, 2023 RadioGel(TM) is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor. The hydrogel is a yttrium-90 …See details»

Radiogel Precision Radionuclide Therapy Receives FDA …

Dec 20, 2023 RadioGel(TM) is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor. The hydrogel is a yttrium-90 …See details»

Contact Us - RadioGelâ„¢

Vivos Inc. Suite N288 1030 N Center Parkway, Kennewick, Washington 99336, United States. [email protected]See details»

Radiogel™ Precision Radionuclide Therapy™ Receives FDA …

Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision …See details»

IDE Submission - RadioGelâ„¢

The filing was an amendment, addressing the FDA comments to our previous application (Q211938/S001). Today’s IDE submission marks our first filing with the FDA following the …See details»

Radiogelâ„¢ Precision Radionuclide Therapyâ„¢ Receives FDA

Dec 20, 2023 --Vivos Inc., Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a …See details»

Radiogelâ„¢ Precision Radionuclide Therapyâ„¢ Receives FDA

Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision …See details»

The Science of RadioGel®

Y-90 RadioGel® employs the high energy (2.3 MeV maximum), short-path length (11 mm maximum), pure beta-particle-emitting radionuclide yttrium-90 (physical half-life of 2.67 days), …See details»

Vivos Inc. Extended its IsoPet® Precision Radionuclide TherapyTM …

Sep 30, 2024 RadioGel ® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options …See details»

Radiogelâ„¢ Precision Radionuclide Therapyâ„¢ Receives FDA

Dec 20, 2023 RadioGel â„¢ is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor. The hydrogel is a yttrium-90 …See details»

RadioGel Precision Radionuclide Therapy Receives FDA ... - EQS …

Dec 20, 2023 RICHLAND, WA – (NewMediaWire) – December 20, 2023 — Vivos Inc. (OTCQB: RDGL), is pleased to announce that the Food and Drug Administration has granted RadioGel …See details»

Research Papers | RadioGelâ„¢

The yttrium-90-RadioGel® agent was designed to provide a safe, effective, localized, high-dose beta radiation for treating solid tumors. The properties of 90Y-RadioGel® also make it a …See details»

linkstock.net © 2022. All rights reserved